Jordan Burnham, MD
Ophthalmology · Denham Springs, LANPI 1427312800
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,903 of the $6,331 with a category attached, or 61.7%. 23 manufacturers reported payments, led by Alimera Sciences, Inc. at 52.1% of the total. Reporting peaked in 2021 at $2,007 and has fallen 53.9% since, to $926 in 2025.
Across 119 payments — averaging $53.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alimera Sciences, Inc.$3K
- Regeneron Healthcare Solutions, Inc.$605
- AbbVie$529
- Apellis Pharmaceuticals, Inc.$368
- Genentech USA, Inc.$363
- Astellas Pharma US Inc$277
- plus $892 from 17 others
What the payments were for
- Speaking & faculty fees$2,40038%
- Food & beverage$3,90362%
- Education$280%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alimera Sciences, Inc. | 23 | $3,297 |
| Regeneron Healthcare Solutions, Inc. | 21 | $605 |
| AbbVie(2 entities) | 19 | $529 |
| Apellis Pharmaceuticals, Inc. | 10 | $368 |
| Genentech USA, Inc. | 10 | $363 |
| Astellas Pharma US Inc | 7 | $277 |
| Eyepoint US, Inc. | 3 | $181 |
| Bausch & Lomb Americas Inc. | 3 | $126 |
| Coherus Oncology, Inc. | 4 | $92 |
| Neurotech Pharmaceuticals, Inc. | 1 | $90 |
| Astellas Pharma Global Development | 2 | $52 |
| Sandoz | 2 | $48 |
| Novartis | 3 | $48 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $47 |
| Dutch Ophthalmic, USA | 1 | $37 |
| Dompe US, Inc. | 1 | $27 |
| Kala Pharmaceuticals, Inc. | 1 | $26 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Iridex Corporation | 1 | $22 |
| Biotissue Holdings Inc. | 1 | $20 |
| Harrow Eye, LLC | 1 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
| Optos, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,331 in reported general payments places this provider in the 85th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 212 | $9,123 |
| Ofloxacin | 129 | $2,128 |
| Latanoprost | 61 | $447 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 24 | $268 |
| Brimonidine Tartrate | 26 | $257 |
| Timolol Maleate | 13 | $65 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Denham Springs
- Blake WilliamsonBaton Rouge$443K
- Rebecca MetzingerNew Orleans$63K
- Ze ZhangNew Orleans$44K
- Wyche ColemanShreveport$35K
- Peter KastlNew Orleans$32K
- Bryan VekoviusShreveport$29K
- Christopher ShelbyShreveport$27K
- Arthur DelahoussayeHouma$26K
- Michael RedmondAlexandria$24K
- Eric ReishAlexandria$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.